GKOS stock forecast
Our latest prediction for Glaukos Corp.'s stock price was made on the Nov. 28, 2018 when the stock price was at 62.39$.
In the short term (2weeks), GKOS's stock price should outperform the market by 0.76%. During that period the price should oscillate between -6.43% and +7.03%.
In the medium term (3months), GKOS's stock price should outperform the market by 4.43%. During that period the price should oscillate between -14.08% and +20.00%.Get email alerts
Create a solid portfolio with GKOS
About Glaukos Corp.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
At the moment the company generates 181M USD in revenues.
On its last earning announcement, the company reported a loss of -0.37$ per share.
The book value per share is 4.21$
Three months stock forecastNov. 28, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|